Duloxetine Hydrochloride Capsule, Delayed Release
Product Images NDC 33342-160

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 33342-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine 20mg 60s Bottle

Duloxetine Hydrochloride 20 mg delayed-release capsules label from Macleods Pharmaceuticals Limited. The label shows the product name, strength, dosage form, manufacturer (Macleods Pharma USA, Inc.), and container size of 60 capsules. It includes storage instructions and pharmacist dispensing guidance. The label also displays NDC 33342-160-09 and contains barcodes.*

FDA Label Image

Duloxetine 30mg 30s Bottle

Label of Duloxetine Delayed-Release Capsules, USP 30 mg by Macleods Pharmaceuticals Limited. The label includes dosage form as delayed-release capsules, strength 30 mg, and package quantity of 30 capsules. It also shows storage instructions, manufacturer details including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., and a barcode.*

FDA Label Image

Duloxetine 60mg 1000s Bottle

Label for Duloxetine Hydrochloride 60 mg delayed-release capsules by Macleods Pharmaceuticals Limited. The label includes dosing and storage instructions, pharmacist guidance to dispense the medication guide, and manufacturing details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd. The package count is 1000 capsules with an NDC of 33342-162-44.*

FDA Label Image

Duloxetine 60mg 30s Bottle

Packaging label for Duloxetine Hydrochloride delayed-release capsules, USP 60 mg, distributed by Macleods Pharma USA, Inc. The label includes dosage information, storage instructions, and a 30-capsule count. Manufactured by Macleods Pharmaceuticals Ltd in Baddi, Himachal Pradesh, India.*

FDA Label Image

Fig-1 (Duloxetine Fig 1)

A Kaplan-Meier survival curve graph depicting the proportion of patients with relapse over time from randomization to relapse (days). Two treatment groups are compared: Duloxetine and Placebo. The y-axis shows the proportion of patients with relapse, and the x-axis indicates the time in days, up to about 200 days.*

FDA Label Image

Fig-2 (Duloxetine Fig 2)

A line graph showing the proportion of patients with relapse over time from randomization (days) comparing Duloxetine and Placebo treatments. The x-axis represents time in days up to 300, and the y-axis represents the proportion of patients with relapse from 0 to 1. Two lines are shown: one for Placebo (dashed) and one for Duloxetine (solid), with the Placebo line having a higher relapse proportion over time.*

FDA Label Image

Fig-3 (Duloxetine Fig 3)

A line chart showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. Each group is represented by a different line with distinct markers, illustrating the distribution of patient improvement percentages across increasing pain improvement thresholds from 0% to 100%.*

FDA Label Image

Fig-4 (Duloxetine Fig 4)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg dosed twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo groups, depicting trends in pain improvement across these treatments.*

FDA Label Image

Fig-7 (Duloxetine Fig 7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily. The graph shows two curves, indicating patient improvement rates across varying pain reduction percentages, with Duloxetine consistently outperforming placebo.*

FDA Label Image

Fig-8 (Duloxetine Fig 8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Hydrochloride 60 mg once daily and placebo. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines represent Duloxetine 60 mg and placebo with percentages decreasing as pain improvement increases.*

FDA Label Image

Fig-9 (Duloxetine Fig 9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent placebo and Duloxetine treatment, illustrating patient improvement distributions across pain improvement levels.*

FDA Label Image

Duloxetine Fig 5

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Three lines represent treatment groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, comparing patient improvement rates across varying pain improvement percentages.*

FDA Label Image

Duloxetine Fig 6

Line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Four groups are compared: Duloxetine Hydrochloride 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The graph presents trends of patient improvement percentages across increasing levels of pain improvement.*

FDA Label Image

Str (Duloxetine Str)

Chemical structure diagram of Duloxetine Hydrochloride showing its molecular configuration including a naphthalene group, a thiophene ring, and the hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.